Overview

An Exploratory Study of the Effects of a Single Dose of QAX576 (an Interleukin-13 Monoclonal Antibody) on Simulated Hayfever

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will investigate whether a single dose QAX576 (an interleukin-13 monoclonal antibody) gives protection against a model of hayfever
Phase:
Phase 2
Details
Lead Sponsor:
Novartis
Treatments:
Antibodies
Antibodies, Monoclonal
Immunoglobulins